News Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
6.090 ^USD	-0.49%		-19.55%	-30.95%

02-12	Vanda Pharmaceuticals Inc files for mixed shelf offering of up to $200 million - SEC filing	RE
02-12	Vanda Pharmaceuticals Inc., Q4 2025 Earnings Call, Feb 11, 2026

All News

02-12	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA	PR
02-12	Vanda Pharmaceuticals Inc files for mixed shelf offering of up to $200 million - SEC filing	RE
02-12	Vanda Pharmaceuticals Inc., Q4 2025 Earnings Call, Feb 11, 2026
02-11	Vanda: Q4 Earnings Snapshot	AQ
02-11	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results	PR
02-11	Vanda Pharmaceuticals Inc. Provides Earnings Guidance for the Full Year 2026	CI
02-11	Vanda Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-04	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026	PR
01-29	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA	PR
01-22	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA	PR
01-15	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA	PR
01-08	Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ®? Supplemental New Drug Application for Jet Lag Disorder	CI
01-08	Top Premarket Decliners	MT
12-31	Health Care Down on Mixed Drug Sales View -- Health Care Roundup	DJ
12-31	Wall Street ends year's final session lower but ends 2025 with big annual gains	RE
12-31	Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	MT
12-31	Top Premarket Gainers	MT
12-31	Stocks Decline Pre-Bell Ahead of Final Trading Session of 2025	MT
12-31	US stock futures inch down in thin trading, but Wall Street eyes yearly gains	RE
12-31	Vanda Pharmaceuticals Says FDA Has Approved Nereus for Motion-Induced Vomiting; Shares Rise Pre-Bell	MT
12-31	Vanda Pharmaceuticals Announces FDA Approval of Nereus? (tradipitant) for the Prevention of Vomiting Induced by Motion	CI
12-31	Vanda Pharma Shares Rise After FDA Approves Motion Sickness Treatment	DJ
12-15	Vanda Pharmaceuticals Rises on FDA Biologics License Application	DJ
12-15	Vanda Pharmaceuticals Inc. Announces Submission of Biologics License Application to FDA for Imsidolimab for Treatment of Generalized Pustular Psoriasis	CI
12-15	Vanda Pharmaceuticals Submits Biologics License Application to US FDA for Generalized Pustular Psoriasis Drug	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

All News

Filters